Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.81 |
| ▸ | CES1 | P23141 | 12/20 | 0.81 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156255 | 0.90 | CES2 (1.00) | CES2CES1CA1CA2CA4 | |
| SCHEMBL2156965 | 0.87 | CES2 (1.00) | CES2CES1HCAR1CA1TTR | |
| SCHEMBL28412506 | 0.78 | CES2 (0.76) | CES2CES1CA1CA2CA4 | |
| SCHEMBL4843572 | 0.77 | CES2 (0.74) | CES2CES1 | |
| SCHEMBL4414671 | 0.75 | CES2 (0.75) | CES2CES1HCAR1CA1TTR | |
| SCHEMBL7260110 | 0.74 | CES2 (0.73) | CES2CES1 | |
| SCHEMBL15956471 | 0.74 | CES2 (0.73) | CES2CES1HCAR1SLC6A3 | |
| SCHEMBL9693658 | 0.74 | CES2 (0.65) | CES2CES1HCAR1CA1CA2 | |
| SCHEMBL9693525 | 0.74 | CES2 (0.70) | CES2CES1CA1CA2CA4 | |
| SCHEMBL28312590 | 0.74 | CES2 (0.70) | CES2CES1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CES2 4307/4885CES1 3870/4885HCAR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.